Algert Global LLC Nektar Therapeutics Transaction History

Algert Global LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$0.49 - $0.96 $13,524 - $26,496	-27,600 Reduced 48.4%	29,430 $27,000
Q4 2023 Feb 14, 2024	SELL	$0.42 - $0.57 $51,912 - $70,452	-123,600 Reduced 68.43%	57,030 $32,000
Q2 2023 Aug 14, 2023	BUY	$0.53 - $1.03 $95,733 - $186,048	180,630 New	180,630 $104,000
Q4 2022 Feb 13, 2023	SELL	$2.03 - $4.28 $261,463 - $551,264	-128,800 Reduced 27.04%	347,612 $786,000
Q3 2022 Nov 15, 2022	BUY	$3.04 - $5.14 $131,972 - $223,137	43,412 Added 10.03%	476,412 $1.53 Million
Q2 2022 Aug 15, 2022	BUY	$3.17 - $6.17 $1.14 Million - $2.22 Million	359,990 Added 493.07%	433,000 $1.65 Million
Q1 2022 May 16, 2022	BUY	$4.16 - $13.72 $303,721 - $1 Million	73,010 New	73,010 $394,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.